HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I-II study of m-AMSA administered as a continuous infusion.

Abstract
In vitro studies of 4'(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) with L1210 leukemia cells have demonstrated that a given level of DNA breakage and intraceLlular m-AMSA concentration depends upon the presence of a continuous concentration of extracellular drug and that cytotoxicity increases with an increasing duration of drug exposure. Since previous studies had shown that free m-AMSA has a half-life of 6-8 hours, a trial of m-AMSA given as a continuous infusion was undertaken in patients with solid tumors and lymphomas. Patients were treated with 30 mg/m2/day x 3, 30 mg/m2/day x 4, or 40 mg/m2/ day x 3. Myelosuppression was dose-limiting and occurred at about Day 13 after the start of the infusion. Recovery was noted by Day-21. There was no evidence of cumulative hematologic toxicity. The maximally tolerated dose was 30 mg/m2/day x 3 in our patient population. Mild phlebitis occurred in all patients. There were no instances of gastrointestinal, hepatic, renal, cardiac, or neurologic toxic reactions. Evidence of some antitumor effect was seen in three patients. We conclude that it is possible to given m-AMSA as a continuous infusion and that studies should be undertaken in patients with acute myelogenous leukemias to compare the efficacy of m-AMSA infusion with conventional bolus administration as a means to enhance the duration of response.
AuthorsK C Micetich, L A Zwelling, P Gormley, R C Young
JournalCancer treatment reports (Cancer Treat Rep) Vol. 66 Issue 10 Pg. 1813-7 (Oct 1982) ISSN: 0361-5960 [Print] United States
PMID6897013 (Publication Type: Journal Article)
Chemical References
  • Aminoacridines
  • Antineoplastic Agents
  • Amsacrine
Topics
  • Aminoacridines (administration & dosage, adverse effects, therapeutic use)
  • Amsacrine
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Bone Marrow (drug effects)
  • Drug Evaluation
  • Female
  • Humans
  • Kinetics
  • Leukocyte Count
  • Male
  • Middle Aged
  • Phlebitis (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: